Exhibitors Search
AIGENDRUG
Booth no.
F60/P70
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|9 Bongcheon-ro 31-gil, Gwanak-gu, Seoul, Republic of Korea |
|
Tel
|
|+82-70-4902-0716 |
|
Exhibits
|
| 1. DrugVLAB: An AWS-Based End-to-End Drug Discovery and Development Platform, 2.Custom AI R&D-to-Service Technology and Partnership |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup , Digital Health / Medical Device Company |
Exhibitor Information
AIGENDRUG is an AI-driven, end-to-end drug discovery company providing integrated solutions through its DrugVLAB™ platform and CRO services. The company supports the full workflow from target discovery and lead identification, design, and optimization to efficacy, toxicity, and patient-level drug response prediction. Built on bioinformatics and AI capabilities accumulated through more than 200 research publications, AIGENDRUG combines real assay data with Activity Cliff-Aware Learning and Assay-Enriched Fragment Generation in a Human-in-the-Loop framework. This enables its AI to learn subtle structure?activity differences and incorporate experimental feedback. AIGENDRUG applies these technologies across multiple therapeutic areas, including oncology, antibiotics, and pain-related diseases, while validating its capabilities through industry collaborations, proprietary pipelines, and wet-lab experiments.
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : DrugVLAB™ AWS cloud Drug Design and Evaluation PlatformDrugVLAB™ is an AWS-based modular AI platform that connects molecular design, efficacy assessment, and safety evaluation within a unified drug discovery workflow. It integrates target- and mechanism-specific molecule design, fragment-based generation, cell- and patient-level drug response prediction, and multi-organ toxicity assessment to prioritize promising candidates. Its Medical Chemist-in-the-Loop technology learns activity cliffs and assay-positive fragments from experimental data, generates new candidates, and feeds newly measured assay results back into the next design cycle. By continuously connecting AI prediction, medicinal-chemistry expertise, and experimental evidence, DrugVLAB enables iterative generation, evaluation, and refinement of drug candidates.
-
Product Name : Custom AI R&D-to-Service Technology and PartnershipAIGENDRUG provides customized AI R&D-to-Service solutions that connect research questions and proprietary data to deployable, working AI systems. Through collaborative R&D, we define the problem and objectives, design data and validation strategies, and develop, evaluate, and refine fit-for-purpose AI models. The resulting models are implemented as Web, API, and cloud-based services and integrated into existing research environments, with support for deployment, monitoring, operation, and maintenance. Backed by hands-on experience developing and operating DrugVLAB™, AIGENDRUG goes beyond model delivery to build practical AI systems that partners can continuously use in real R&D workflows.
KYUNGYON EXHIBITION CORP.
